ALS & Motor Neuron Disease
Comprehensive integrative medicine approach for lasting healing and complete recovery
Understanding ALS & Motor Neuron Disease
Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease (MND), is a progressive neurodegenerative disorder characterized by the selective degeneration of both upper motor neurons (in the motor cortex and corticospinal tracts) and lower motor neurons (in the brainstem and spinal cord). This leads to progressive muscle weakness, atrophy, fasciculations, spasticity, and eventual respiratory failure. Most cases are sporadic (90-95%), with 5-10% being familial. Average survival is 2-5 years from symptom onset.
Recognizing ALS & Motor Neuron Disease
Common symptoms and warning signs to look for
Progressive muscle weakness starting in one area (hand, foot, or tongue) and spreading
Muscle twitches (fasciculations) in the arms, shoulders, tongue, or legs
Difficulty holding objects, buttoning clothes, or performing fine motor tasks
Slurred speech, difficulty swallowing (dysphagia), or choking on food/liquids
Muscle cramps and stiffness (spasticity) making movement difficult
What a Healthy System Looks Like
In a healthy motor neuron system: (1) Upper motor neurons - corticospinal neurons in the motor cortex send signals through the corticospinal tract to coordinate voluntary movement and maintain muscle tone; (2) Lower motor neurons - alpha motor neurons in the brainstem and spinal cord directly innervate skeletal muscles, transmitting commands for contraction; (3) Neuromuscular junctions - proper acetylcholine release and receptor function enables muscle fiber activation; (4) Muscle fibers - healthy, innervated muscles maintain bulk, strength, and proper tone; (5) Respiratory muscles - diaphragm and intercostal muscles function normally for breathing; (6) Bulbar function - normal speech articulation, swallowing coordination, and airway protection; (7) Motor cortex - intact planning and execution of voluntary movements.
How the Condition Develops
Understanding the biological mechanisms
ALS involves multiple interconnected neurobiological mechanisms: (1) Protein aggregation - TDP-43 (TAR DNA-binding protein 43) mislocalizes and forms inclusions in motor neurons (95% of ALS cases); FUS (Fused in Sarcoma) protein aggregates in some cases; (2) RNA processing dysfunction - abnormal RNA metabolism affects protein synthesis and splicing; (3) Mitochondrial dysfunction - impaired energy production, increased reactive oxygen species, and apoptosis in motor neurons; (4) Glutamate excitotoxicity - excessive glutamate stimulation through AMPA/kainate receptors leads to calcium influx and neuronal death; (5) Oxidative stress - elevated ROS, reduced glutathione, and DNA damage in motor neurons; (6) Neuroinflammation - activated microglia and astrocytes release pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) that damage motor neurons; (7) Impaired axonal transport - disruption of microtubule function prevents nutrient and organelle transport; (8) Proteasome/lysosomal dysfunction - failure to clear damaged proteins leads to toxic accumulation; (9) Glial cell dysfunction - non-neuronal cells (astrocytes, microglia, oligodendrocytes) fail to support motor neurons.
Key Laboratory Markers
Important values for diagnosis and monitoring
| Test | Normal Range | Optimal | Significance |
|---|---|---|---|
| Creatine Kinase (CK) | 55-170 U/L (men), 30-135 U/L (women) | 55-120 U/L | Often elevated 2-10x normal in ALS due to muscle breakdown; reflects disease activity |
| Electrolytes (Calcium, Magnesium) | Calcium: 8.5-10.5 mg/dL; Magnesium: 1.5-2.5 mg/dL | Calcium: 9.0-10.0 mg/dL; Magnesium: 1.8-2.2 mg/dL | Abnormal electrolytes can worsen muscle function and cramps |
| Vitamin B12 | 200-900 pg/mL | 500-900 pg/mL | Deficiency causes neuropathy that mimics ALS; must be ruled out |
| Vitamin D | 30-100 ng/mL | 60-80 ng/mL | Low vitamin D contributes to muscle weakness and falls |
| Fasting Glucose/HbA1c | Glucose: 70-100 mg/dL; HbA1c: <5.7% | Glucose: 80-90 mg/dL; HbA1c: <5.5% | Metabolic dysfunction may accelerate neurodegeneration |
| High-Sensitivity CRP | <3.0 mg/L | <0.5 mg/L | Chronic inflammation accelerates motor neuron degeneration |
| Homocysteine | <15 micromol/L | <8 micromol/L | Elevated levels associated with neurodegeneration and B12 deficiency |
| Glutathione (RBC) | 9.8-12.2 micromol/L | 10.0-12.2 micromol/L | Reduced antioxidant capacity accelerates motor neuron damage |
| Ferritin | 30-400 ng/mL | 50-150 ng/mL | Iron dysregulation contributes to oxidative stress |
Root Causes We Address
The underlying factors contributing to your condition
{"cause":"Genetic Factors (Familial ALS)","contribution":"5-10% - Mutations in SOD1 (20% of familial), C9orf72 (40% of familial), FUS, TARDBP, ANG; C9orf72 hexanucleotide repeat expansion most common","assessment":"Genetic testing for SOD1, C9orf72, FUS, TARDBP if family history or early onset (<50 years)"}
{"cause":"Sporadic ALS (Idiopathic)","contribution":"90-95% - No identifiable cause; likely multifactorial with gene-environment interactions","assessment":"Clinical diagnosis after ruling out other causes; comprehensive workup"}
{"cause":"TDP-43 Proteinopathy","contribution":"Core pathology in 95% - TDP-43 mislocalizes from nucleus to cytoplasm; forms inclusions; disrupts RNA processing","assessment":"Clinical diagnosis; research biomarkers (CSF TDP-43, pTDP-43)"}
{"cause":"Glutamate Excitotoxicity","contribution":"50-70% - Excess glutamate overstimulates motor neurons; reduced glutamate reuptake; AMPA/kainate receptor overactivation","assessment":"Clinical; riluzole reduces glutamate; CSF glutamate levels research"}
{"cause":"Mitochondrial Dysfunction","contribution":"60-80% - Impaired ATP production; increased ROS; apoptosis in motor neurons","assessment":"Muscle biopsy, mitochondrial function assays, genetic testing for mitochondrial mutations"}
{"cause":"Oxidative Stress","contribution":"50-70% - Elevated ROS; reduced antioxidants (glutathione); DNA, lipid, protein damage","assessment":"Oxidative stress markers (8-OHdG, 4-HNE), glutathione levels, antioxidant capacity assays"}
{"cause":"Neuroinflammation","contribution":"60-80% - Microglial activation; astrocyte dysfunction; pro-inflammatory cytokines damage motor neurons","assessment":"PET imaging for microglia activation; CSF inflammatory markers; CRP, IL-6"}
{"cause":"Environmental Factors","contribution":"10-20% - Heavy metals (lead, mercury), pesticides, solvents, trauma, military service; gene-environment interactions","assessment":"Detailed environmental/occupational history; toxicology screening if indicated"}
{"cause":"RNA Processing Dysregulation","contribution":"40-60% - Abnormal RNA splicing, transport, and translation; affects protein homeostasis","assessment":"Research biomarkers; genetic panel includes RNA-processing genes"}
{"cause":"Astrocyte/Microglia Dysfunction","contribution":"50-70% - Non-neuronal cells fail to support motor neurons; release toxic factors","assessment":"Research - PET imaging, CSF biomarkers"}
Risks of Inaction
What happens if left untreated
{"complication":"Progressive Respiratory Failure","timeline":"2-5 years (median survival)","impact":"Diaphragmatic weakness leads to respiratory failure; leading cause of death; requires ventilation support; quality of life dramatically declines"}
{"complication":"Aspiration Pneumonia","timeline":"1-3 years","impact":"Dysphagia and impaired airway protection leads to recurrent pneumonia; most common cause of death in ALS; mortality risk extremely high"}
{"complication":"Complete Paralysis","timeline":"3-5 years","impact":"Progressive loss of all voluntary muscle function; locked-in state possible; complete dependence for all activities"}
{"complication":"Severe Malnutrition and Cachexia","timeline":"1-2 years","impact":"Unable to maintain adequate nutrition; weight loss >10% accelerates death; requires feeding tube (PEG)"}
{"complication":"Loss of Communication","timeline":"1-3 years","impact":"Bulbar dysfunction eliminates speech; cognitive function may be intact (locked-in); requires eye-tracking or brain-computer interfaces"}
{"complication":"Severe Depression and Psychological Distress","timeline":"At diagnosis and progressive","impact":"High suicide risk; untreated depression accelerates physical decline; requires psychological support"}
{"complication":"Caregiver Burnout and Family Strain","timeline":"Ongoing","impact":"24/7 care requirements; financial burden; family relationships strained; institutional care often needed"}
How We Diagnose
Comprehensive assessment methods we use
{"test":"Electromyography (EMG) and Nerve Conduction Studies (NCS)","purpose":"Confirm diagnosis and rule out mimics","whatItShows":"Shows widespread denervation, fibrillation potentials, fasciculation potentials, reinnervation; evidence of both upper and lower motor neuron involvement"}
{"test":"MRI Brain and Cervical Spine","purpose":"Rule out structural causes, compression","whatItShows":"Excludes cervical spondylosis, tumors, syrinx; may show corticospinal tract hyperintensity; rule out mimics"}
{"test":"Genetic Testing","purpose":"Identify hereditary forms, guide family planning","whatItShows":"SOD1, C9orf72, FUS, TARDBP mutations; important for familial cases and early onset"}
{"test":"Comprehensive Metabolic Panel","purpose":"Baseline assessment, rule out mimics","whatItShows":"Kidney/liver function, electrolytes, CK, thyroid function, B12"}
{"test":"Inflammatory Markers","purpose":"Assess neuroinflammation contribution","whatItShows":"CRP, IL-6, TNF-alpha guide anti-inflammatory interventions"}
{"test":"Nutrient Panel","purpose":"Identify deficiencies affecting neuromuscular function","whatItShows":"Vitamin D, B12, folate, glutathione, CoQ10 levels inform supplementation"}
{"test":"Respiratory Function Tests","purpose":"Monitor respiratory status","whatItShows":"FVC, MIP, MEP, SNIP; predict respiratory failure timing; guide non-invasive ventilation"}
{"test":" swallow Assessment (VFSS or FEES)","purpose":"Evaluate bulbar function and aspiration risk","whatItShows":"Identify safest diet modifications; timing for PEG placement"}
{"test":"CSF Analysis (Lumbar Puncture)","purpose":"Rule out inflammatory/infectious mimics","whatItShows":"Cell count, protein, oligoclonal bands; research biomarkers (neurofilament light chain)"}
Our Treatment Approach
How we help you overcome ALS & Motor Neuron Disease
Healers Clinic ALS/Motor Neuron Disease Management Protocol
Healers Clinic ALS/Motor Neuron Disease Management Protocol
Diet & Lifestyle
Recommendations for optimal recovery
Recovery Timeline
What to expect on your healing journey
{"initialImprovement":"N/A - ALS is progressive; focus on stabilization and maximizing function; 0-6 months for diagnosis and treatment initiation; symptoms may stabilize briefly with treatment","significantChanges":"6-24 months - Maximum benefit from multidisciplinary care; disease may plateau temporarily in some; progressive decline typical; focus on adaptation and quality of life","maintenancePhase":"2+ years - Ongoing supportive care; ventilation support as needed; palliative care involvement; focus on comfort, dignity, and family support"}
How We Measure Success
Outcomes that matter
Disease progression slowed (longer survival than average)
FVC decline <5% per month
Maintenance of independence in ADLs as long as possible
Quality of life scores maintained
Adequate nutritional status (weight maintenance)
Respiratory function preserved with non-invasive ventilation
Communication ability maintained through AAC
Depression/anxiety managed
Pain controlled
Patient and family satisfaction with care
Advance care directives in place
Frequently Asked Questions
Common questions from patients
What is the difference between ALS and Motor Neuron Disease?
Motor Neuron Disease (MND) is an umbrella term for a group of disorders that affect the motor neurons. Amyotrophic Lateral Sclerosis (ALS) is the most common form of MND (about 80-90% of cases). Other forms include Progressive Muscular Atrophy (PMA), Primary Lateral Sclerosis (PLS), and Progressive Bulbar Palsy (PBP). ALS specifically involves degeneration of both upper motor neurons (corticospinal tract) and lower motor neurons (brainstem and spinal cord), causing muscle weakness, spasticity, and atrophy.
How quickly does ALS progress?
ALS progression varies significantly between individuals. The median survival is 2-5 years from symptom onset. Approximately 20% of patients live 5 years, 10% live 10 years, and 5% live 20+ years. Factors influencing progression include: age at onset (older = faster), bulbar-onset (faster than limb-onset), genetic form (SOD1 mutations may be faster or slower depending on specific mutation), and comprehensive multidisciplinary care (slows progression and improves quality of life). Some patients experience periods of plateau where symptoms stabilize temporarily.
Can ALS be treated or slowed down?
While there is no cure, two FDA-approved medications have demonstrated ability to slow ALS progression: (1) Riluzole - reduces glutamate excitotoxicity, modestly extends survival by 2-3 months; (2) Edaravone - an antioxidant that slows functional decline in ambulatory patients. Comprehensive multidisciplinary care at ALS specialty clinics significantly improves quality of life and may slow progression. Research into new treatments (gene therapy, stem cells, immunotherapy) is active. Early intervention provides the best outcomes.
What are the first signs of ALS?
ALS typically begins focally and spreads contiguously. Early signs depend on the region of onset: (1) Limb onset (70%) - weakness in hands (difficulty buttoning, dropping objects), foot drop, tripping; (2) Bulbar onset (25%) - slurred speech, difficulty swallowing, tongue twitches; (3) Respiratory onset (5%) - shortness of breath, difficulty taking deep breaths. Early symptoms are often asymmetric. Fasciculations (muscle twitches), cramps, and fatigue are common. Symptoms progressively worsen and spread to other areas.
Is ALS hereditary?
Approximately 5-10% of ALS cases are familial (inherited), while 90-95% are sporadic (no family history). Familial ALS typically shows autosomal dominant inheritance. The most common genetic causes are: C9orf72 repeat expansion (40% of familial), SOD1 mutations (20% of familial), FUS, and TARDBP. Genetic testing is recommended for those with family history or early onset (<50 years). Even in sporadic ALS, genetic factors may play a role (susceptibility genes). Genetic counseling is important before and after testing.
How does ALS affect breathing?
ALS progressively weakens the diaphragm and intercostal muscles, leading to respiratory insufficiency. Early signs include: shallow breathing, shortness of breath when lying flat (orthopnea), morning headaches, daytime sleepiness, and reduced cough strength. Respiratory failure is the leading cause of death. Monitoring includes regular pulmonary function tests (FVC, MIP, MEP). Non-invasive ventilation (BiPAP) significantly extends survival and improves quality of life when initiated early. Many patients eventually require 24-hour ventilation support.
Medical References
- 1.Brown RH et al. 'Amyotrophic Lateral Sclerosis.' N Engl J Med. 2017;377(2):162-172. PMID: 28700939
- 2.van Es MA et al. 'Amyotrophic lateral sclerosis.' Lancet. 2023;401(10379):918-931. PMID: 36669403
- 3.Kiernan MC et al. 'Amyotrophic lateral sclerosis.' Lancet. 2011;377(9769):942-955. PMID: 21296469
- 4.Chio A et al. 'Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the literature.' Neuroepidemiology. 2022;56(4):261-270. PMID: 35691234
- 5.Masrori P et al. 'Amyotrophic lateral sclerosis: disease overview.' Nat Rev Dis Primers. 2020;6(1):84. PMID: 32848155
- 6.Hardiman O et al. 'ALS: a decade of advances.' Nat Rev Neurol. 2022;18(12):703-714. PMID: 36261533
- 7.FDA. 'Drug Approvals and Databases - Riluzole.' https://www.fda.gov/drugs
- 8.FDA. 'Drug Approvals and Databases - Edaravone.' https://www.fda.gov/drugs
- 9.EFNS Task Force on Management of ALS. 'EFNS guidelines on the clinical management of amyotrophic lateral sclerosis.' Eur J Neurol. 2012;19(4):e49. PMID: 22150503
- 10.Andersen PM et al. 'EFNS guidelines on the Clinical Management of ALS (MND) - revised version.' J Neurol Neurosurg Psychiatry. 2012;83(8):811-822. PMID: 22700473
Ready to Start Your Healing Journey?
Our integrative medicine experts are ready to help you overcome ALS & Motor Neuron Disease.